Myeloma News and Research RSS Feed - Myeloma News and Research

Inhibition of EZH2 protein could be new strategy to treat multiple myeloma

Inhibition of EZH2 protein could be new strategy to treat multiple myeloma

In a study published in the scientific journal Oncotarget, researchers from Uppsala University show how the protein EZH2 affects the development of multiple myeloma, and that inhibition of EZH2 could be used as a new strategy to treat the disease. [More]
Epigenetic modification may be cause of adult throat cancers linked to alcohol, tobacco use

Epigenetic modification may be cause of adult throat cancers linked to alcohol, tobacco use

A team of researchers at the Research Institute of the McGill University Health Centre has found an epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use. [More]
NCCN publishes new easy-to-understand patient education resources focused on brain cancer

NCCN publishes new easy-to-understand patient education resources focused on brain cancer

The National Comprehensive Cancer Network has published the NCCN Guidelines for Patients and NCCN Quick Guide sheets for Brain Cancer - Gliomas—the first in a series of patient education resources focused on Brain Cancer. [More]
Whitehead Institute researchers identify mechanism underlying cancer drug-resistance

Whitehead Institute researchers identify mechanism underlying cancer drug-resistance

The use of proteasome inhibitors to treat cancer has been greatly limited by the ability of cancer cells to develop resistance to these drugs. [More]
Study shows three-drug combination delays recurrence and lengthens life for myeloma patients

Study shows three-drug combination delays recurrence and lengthens life for myeloma patients

The International Myeloma Foundation today announced the publication in The Lancet of the results of a randomized, phase III trial, conducted by SWOG, a publicly funded international cancer clinical trials network, and led by IMF chairman of the board Brian G.M. Durie, MD. [More]
Researcher develops new method to accurately identify elusive molecules

Researcher develops new method to accurately identify elusive molecules

Among the most important molecules in the living world are sugars or carbohydrates, which play a vital role in life processes. Sugars provide the main source of fuel for the body, protect muscles from damage and contribute to the immune response. [More]
Defective ribosomes linked to aggressive form of multiple myeloma

Defective ribosomes linked to aggressive form of multiple myeloma

20 to 40 percent of the patients with multiple myeloma - a type of leukaemia - have a defect in the ribosome, the protein factory of the cell. [More]
Personalized cancer vaccine improves outcomes for patients with AML, clinical study shows

Personalized cancer vaccine improves outcomes for patients with AML, clinical study shows

A personalized cancer vaccine markedly improved outcomes for patients suffering from acute myeloid leukemia (AML), a potentially lethal blood cancer, in a clinical trial led by investigators at Beth Israel Deaconess Medical Center. [More]
Additions to standard therapy do not improve progression-free survival in patients with multiple myeloma

Additions to standard therapy do not improve progression-free survival in patients with multiple myeloma

Trial results being presented today during the 58th American Society of Hematology Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone. [More]
Clonal hematopoiesis may help predict cancer patients at risk for fatal form of leukemia

Clonal hematopoiesis may help predict cancer patients at risk for fatal form of leukemia

Patients successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms (t-MNs). [More]
Maintaining healthy weight may be key to prevent MGUS progression to multiple myeloma

Maintaining healthy weight may be key to prevent MGUS progression to multiple myeloma

New research shows that excess weight increases the risk that a benign blood disorder will progress into multiple myeloma, a cancer of the blood. [More]
Yale researchers develop new mouse model to understand multiple myeloma

Yale researchers develop new mouse model to understand multiple myeloma

Understanding how multiple myeloma develops and responds to therapies may be easier using a new mouse model developed at Yale University School of Medicine. [More]
Houston Methodist researcher receives $4 million to create triple negative breast cancer immunotherapy

Houston Methodist researcher receives $4 million to create triple negative breast cancer immunotherapy

Scientists at Houston Methodist received support from the U.S. Department of Defense to reprogram cancer patients' immune cells to attack triple negative breast cancer, the most lethal form of breast cancer. [More]
NCCN publishes new resources to help patients understand treatment options for stomach cancer

NCCN publishes new resources to help patients understand treatment options for stomach cancer

This year, it is estimated that more than 26,000 people will be diagnosed with Stomach Cancer in the United States, with nearly one million new cases diagnosed worldwide each year. [More]
Blood cancer treatment linked to distinct increase in molecular age of immune cells

Blood cancer treatment linked to distinct increase in molecular age of immune cells

Certain cancer treatments are known to take a toll on patients, causing side effects like fatigue, nausea and hair loss. Now, scientists are investigating whether some treatments can cause another long-term side effect: premature aging of important disease-fighting cells. [More]
Added benefit not proven for new combination therapy in multiple myeloma

Added benefit not proven for new combination therapy in multiple myeloma

The monoclonal antibody elotuzumab has been approved in combination with lenalidomide and dexamethasone since May 2016 for further treatment of multiple myeloma in adults who have received at least one previous treatment. [More]
Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone. [More]
Scientists identify eight cancer types linked to excess weight and obesity

Scientists identify eight cancer types linked to excess weight and obesity

There's yet another reason to maintain a healthy weight as we age. An international team of researchers has identified eight additional types of cancer linked to excess weight and obesity: stomach, liver, gall bladder, pancreas, ovary, meningioma (a type of brain tumor), thyroid cancer and the blood cancer multiple myeloma. [More]
Socioeconomic factors may contribute to survival of young, white patients with multiple myeloma

Socioeconomic factors may contribute to survival of young, white patients with multiple myeloma

Advances in the treatment of multiple myeloma, a cancer that forms in a type of white blood cell, have led to improved survival predominantly among young and white patients, with less of an increase in survival observed in patients of other ethnicities. [More]
MGH investigators discover key molecules essential for sensing proteasome dysfunction

MGH investigators discover key molecules essential for sensing proteasome dysfunction

Maintaining appropriate levels of proteins within cells largely relies on a cellular component called the proteasome, which degrades unneeded or defective proteins to recycle the components for the eventual assembly of new proteins. [More]
Advertisement
Advertisement